Elicio Therapeutics is committed to transforming the lives of patients by re-engineering the body’s immune response to defeat cancer. They are currently developing vaccines and immunotherapies by combining expertise in materials science and immunology.
In parallel with raising a series A round of funding, CEO Robert Connelly approached Occam to recruit Elicio’s Chief Medical Officer, a role essential to giving shape to Elicio’s platform. The new CMO would be charged with taking ownership of the firm’s preclinical and clinical pipeline as the company moved into a series B round of funding.
Elicio had many programs that were moving toward clinical trials and the company had non-traditional funding sources. This meant that any new executive needed to be able to jump into the science of these novel products quickly, but also have the requisite gravitas to help establish the firm in the traditional biotech investor ecosystem.
Christopher Haqq, M.D., Ph.D., was placed as Elicio’s CMO, also taking on the expanded role of Executive Vice President of Research and Development. Chris had been the first employee at Atara Biotherapeutics, where he helped build an autoimmune and oncology-focused company from scratch. Occam encountered Chris as he was searching for his next company-building experience. The promise of bringing his skills as both a scientist and clinical researcher was enough to convince Elicio to build the position around Chris’ unique talents.